Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 106,113

Document Document Title
WO/2014/203696A1
Provided is a novel anti-epileptic drug for the prevention and/or treatment of epileptic seizures that has a mode of action different from that of conventional anti-epileptic drugs. The anti-epileptic drug comprises as the active ingredi...  
WO/2014/204175A1
The present invention relates to a crystalline form of (2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)benzofuran) and a method for preparing the same. The crystalline form of (2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)benzofuran) according...  
WO/2014/202834A1
The present invention relates to treatment of neuronal injury. The present invention discloses a novel use of an agent and a novel method for promoting neurite out growth and/or neural regeneration in CNS injuries. A novel mechanism of p...  
WO/2014/201986A1
Provided is a mesenchymal stem cell separation method, comprising: A) utilizing collagenase to digest an animal sample, and dispersing cells contained in the animal sample to obtain a cell mixture comprising stem cells; B) introducing th...  
WO/2014/202763A1
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof. Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or i...  
WO/2014/205338A3
Described herein are methods and compositions relating to modulating the permeability of the blood-brain barrier, e.g. increasing or decreasing the permeability of the blood-brain barrier for therapeutic purposes.  
WO/2014/202493A1
The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar is a heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O; R1 is hydrogen, lower alkyl, halogen, amino, di...  
WO/2014/202597A1
Disclosed is a compound having the formula a) or b); a: R = CH3; b: R = CH2CH3, and its use in the prevention and/or treatment of Alzheimer's disease.  
WO/2014/202578A1
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting, substituted phenyl-2,3-benzodiazepines of general formula (I), in which X, R1a, R1b, R1c, R2, R3, R4, and R5 have the meanings specified in the description, ...  
WO/2014/202999A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1 , R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in th...  
WO/2014/202646A1
The present invention relates to the use of (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphe noxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical com...  
WO/2014/202833A1
The present invention relates to treatment of neuronal injuries. Specifically, the present invention relates to novel mechanisms and means for promoting neurite outgrowth, neural regeneration and/or maintenance of neurites (axons and den...  
WO/2014/203150A1
Disclosed are compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the α7 subtype, their tautomeric forms, stereoisomers, an...  
WO/2014/198808A1
The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.  
WO/2014/198592A1
The invention relates to a compound of formula (I), wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2014/200078A1
The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound indicated by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), Ra and Rb together, and Rd and Re together ...  
WO/2014/198854A1
The present invention relates to novel 6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazin- 6-yl derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, in particular BACE1 and/or BACE2 (wherein BACE1, is...  
WO/2014/200018A1
A therapeutic effect of the administration of interferon-β (IFN-β) on a relapsing-remitting multiple sclerosis (RRMS) patient can be predicted and an RRMS case, wherein the administration can be hardly continued because of the occurren...  
WO/2014/200075A1
Provided are 4-alkynyl imidazole derivatives represented by general formula (I) and pharmacologically permissible salts thereof. The derivatives have excellent EP4 receptor antagonist effects and are useful as medicines for treating dise...  
WO/2014/198880A1
The invention provides a compound of formula (I) wherein R2-R10 represent different meanings, and pharmaceutically acceptable salts thereof. The invention also provides synthetic procedures for preparing the compounds of formula (I), pha...  
WO/2014/200882A1
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.  
WO/2014/198842A1
The present invention is related to a product comprising a pentacyclic triterpene and hydroxytyrosol or derivatives thereof, uses, and pharmaceutical composition thereof.  
WO/2014/197961A1
The present invention generally concerns new non-agglomerating bioconjugates of amylin-mimetic compounds with polyethylene glycol, and their use mainly in the treatment of diseases associated with extracellular amyloid deposition or accu...  
WO/2014/198851A1
The present invention relates to novel 5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, in particular BACE1 and/or BACE2 (wherein BACE1, is als...  
WO/2014/198853A1
The present invention relates to novel 5,6-dihydroimidazo[1,5-a]pyrazinyl derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, in particular BACE1 and/or BACE2 (wherein BACE1, is also known ...  
WO/2014/199960A1
The present invention provides a novel compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for prophylaxis or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive imp...  
WO/2014/199905A1
A medicament for therapeutic and/or preventive treatment of Alzheimer's disease, which comprises a combination of a retinoic acid receptor (RAR) agonist such as Am80 and a retinoid X receptor (RXR) agonist such as HX630.  
WO/2014/200350A1
The invention relates to a composition for use in the treatment of neurobehavioral disorders, a Cannabis plant extract comprising Cannabinolpreferably with other constituents of this plantfor such use and a method for the extraction of p...  
WO/2014/200091A1
 Provided are an agent for inhibiting the aggregation and an agent for lowering the toxicity of Aβ peptide, as well as an agent for the prevention and treatment of Alzheimer's disease. An Aβ oxidant that oxidizes one or more amino ac...  
WO/2014/200356A1
The present invention relates to a formulation comprisingfresh marine oil in an oil-in- water emulsion and resveratrol or derivatives thereoffor use in treating, delaying and/or preventing Alzheimer's Diseaseor symptoms associated with A...  
WO/2014/199455A1
The purpose of the present invention is to provide a patch preparation containing memantine or a pharmaceutically acceptable salt thereof, the patch preparation being produced while inhibiting memantine volatilization to a sufficient lev...  
WO/2014/200961A1
Compositions including an effective amount of each of phosphatidyl serine, choline, and oleic acid, and methods for improving cognitive performance that include administering such compositions to a subject, are described herein. The comp...  
WO/2014/199645A1
The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in...  
WO/2014/199935A1
[Problem] To provide a prophylactic or treatment agent for body weight increase or obesity being a side effect of antidepressants, antipsychotic drugs, analgesics, or treatment agents for fibromyalgia. [Solution] A prophylactic or treatm...  
WO/2014/195311A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also dir...  
WO/2014/195848A1
Disclosed are an alpha 7 nAChR receptor modulator compound, 4- (5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)- 1,4-dimethyl- lH-pyrrol-3- yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical comp...  
WO/2014/197775A1
A compound useful as a Sirt2 or Sirt5 inhibitor having the formula (1) wherein: R1 is a hydrocarbon group having at least two carbon atoms connected by carbon-carbon bonds, wherein said hydrocarbon group is optionally endcapped by a neut...  
WO/2014/195593A2
The invention relates to compounds of formula (I) as well as to neurogenic enantiomers thereof, acid salts thereof, hydrates thereof or to solvation products thereof. Among a large number of possible meanings, X is a halogen, Y is an oxy...  
WO/2014/195553A1
The invention relates to a compound of formula (I), where R is selected from a methyl group or an ethyl group (I), the hydroxy acid forms of said compound, the pharmaceutically acceptable salts of said hydroxy acids, and pharmaceutically...  
WO/2014/194975A1
The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-eth yl-1-(pyrimidin-5-yl)-1 H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, ...  
WO/2014/196658A1
Provided is a therapeutic drug for neuromyelitis optica. Specifically provided is an antibody or a functional fragment thereof that specifically binds to the extracellular domain of aquaporin-4, and includes: a heavy chain variable regio...  
WO/2014/195322A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/197744A1
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products...  
WO/2014/195352A1
The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and...  
WO/2014/196644A1
The inventors perfected the present invention as a result of a study into IK1 channel activators and a confirmation that a benzothiophene compound exhibits efficacy against visceral pain, inflammatory pain, osteoarthritic pain, neuropath...  
WO/2014/194991A1
A pharmaceutical formulation, comprising agomelatine in the form of agomelatine co-crystal with a co-crystal former selected from the group of organic acids in an amount corresponding to 15 - 22 mg agomelatine dose per one dosage unit an...  
WO/2014/195321A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/195323A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/190440A9
The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compou...  
WO/2014/193060A1
The present invention relates to the concomitant administration of a human bone marrow-derived mesenchymal stem cell (hBM-MSC) and minocycline, and alleviates the clinical severity of multiple sclerosis compared to a conventional separat...  

Matches 651 - 700 out of 106,113